This article first appeared on GuruFocus.

Revenue: $99 million for Q4, a 17% increase year over year; $376.6 million for fiscal 2025, a 20% increase over fiscal 2024.

Gross Margin: 51.3% for Q4; 50.7% for fiscal 2025, up from 42.6% in fiscal 2024.

Sinbio Revenue: $39.5 million for Q4, a 17% increase year over year; $145 million for fiscal 2025, a 17% increase over fiscal 2024.

NGS Revenue: $53 million for Q4, a 16% increase year over year; $208.1 million for fiscal 2025, a 23% increase over fiscal 2024.

Biopharma Revenue: $6.4 million for Q4, a 22% increase year over year; $23.5 million for fiscal 2025, a 15% increase over fiscal 2024.

Operating Expenses: $80.8 million for Q4; $327.3 million for fiscal 2025.

Adjusted EBITDA: Loss of $7.8 million for Q4, an improvement of $9.2 million year over year; Loss of $46.9 million for fiscal 2025, an improvement of $46.6 million over fiscal 2024.

Cash Flow from Operating Activities: Net cash used was $47.6 million for the 12 months ended September 30, 2025, compared to $64.1 million for the equivalent period in 2024.

Capital Expenditures: $28 million for fiscal 2025.

Cash Equivalents and Short-term Investments: Approximately $232.4 million at the end of fiscal 2025.

Guidance for Fiscal 2026: Expected total revenues of $425 million to $435 million, growth of 13% to 15.5% year over year.

Warning! GuruFocus has detected 2 Warning Sign with TWST.

Is TWST fairly valued? Test your thesis with our free DCF calculator.

Release Date: November 14, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Twist Bioscience Corp (NASDAQ:TWST) reported a record quarter with $99 million in revenue, exceeding guidance and marking an 11th consecutive quarter of growth.

The company achieved a gross margin of 51.3% for the quarter and 50.7% for the year, up from 42.6% in fiscal 2024, indicating improved operational efficiency.

Revenue from the Synbio segment increased by 17% year over year, driven by the success of the Express portfolio.

The company is seeing significant growth in AI-enabled drug discovery, with orders from AI discovery projects growing by more than $25 million compared to fiscal 2024.

Twist Bioscience Corp (NASDAQ:TWST) is planning to introduce a new express product for minimal residual disease (MRD) in early 2026, which could enhance cancer diagnosis and treatment.

Despite revenue growth, Twist Bioscience Corp (NASDAQ:TWST) reported an adjusted EBITDA loss of approximately $46.9 million for fiscal 2025.

The company faces a temporary 'air pocket' in NGS revenue due to a customer transitioning from research to commercial, impacting Q1 fiscal 2026 revenue.

Operating expenses, excluding cost of revenues, remained relatively flat at $327.3 million, indicating limited cost reduction progress.

The company is still not profitable, with a path to adjusted EBITDA breakeven expected by the end of fiscal 2026.

Twist Bioscience Corp (NASDAQ:TWST) has a relatively small market presence in China, contributing only about 1% of total revenue for fiscal 2025.

Q: Can you explain the factors affecting gross margins and when you expect to return to higher incremental margins? A: Adam Laponis, CFO, explained that while the company has seen significant growth in gross margins over the past two years, there are some tough comparisons due to customer mix. They expect to continue seeing 75-80% incremental margins on average, but there will be some variability. The focus remains on revenue growth and optimizing gross profit.

Q: What are the growth expectations for the NGS segment, and how should we think about long-term growth for this business? A: Adam Laponis, CFO, stated that they expect to return to 20% growth by the fourth quarter of fiscal 2026. The company anticipates growth from MRD and other new product introductions, with about 1-2% of overall growth coming from the MRD business in 2026.

Q: Can you elaborate on the sustainability and momentum of the biopharma orders driven by AI? A: Patrick Finn, President and COO, highlighted the strategic importance of the biopharma business and its integration with the synbio product offering. The AI potential leverages Twist's throughput and scale, supporting the offering and positioning the company well for future growth.

Q: How are you approaching pricing for the MRD Express product, and what are the expected margins? A: Patrick Finn, President and COO, mentioned that pricing has not been set yet, but the company aims to enable customers at scale. They plan to share value with customers, focusing on speed and de-risking supply chain vulnerabilities.

Q: What is the underlying growth for NGS excluding the large customer impact in fiscal 2026? A: Adam Laponis, CFO, indicated that excluding the growth from the large customer, the underlying growth for NGS would be closer to 20% in fiscal 2025, and a similar dynamic is expected for fiscal 2026.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.